We found that Gemcitabine (GEM), a first-line chemotherapeutic drug broadly applied in pancreatic cancer treatment, could lead to a dose-dependent increase in TLR3 expression, as well as increased nuclear levels of TLR3 in Panc1 and Cfpac pancreatic cancer cells (Fig. 1d). Here, TLR3 is linked to pancreatic neoplasm.